Affiliation1The University of Liverpool, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool L69 3GA, UK
MetadataShow full item record
AbstractEndocrine therapy forms a central modality in the treatment of estrogen receptor positive breast cancer. The routine use of 5 years of adjuvant tamoxifen has improved survival rates for early breast cancer, and more recently has evolved in the postmenopausal setting to include aromatase inhibitors. The optimal duration of adjuvant endocrine therapy remains an active area of clinical study with recent data supporting 10 years rather than 5 years of adjuvant tamoxifen. However, endocrine therapy is limited by the development of resistance, this can occur by a number of possible mechanisms and numerous studies have been performed which combine endocrine therapy with agents that modulate these mechanisms with the aim of preventing or delaying the emergence of resistance. Recent trial data regarding the combination of the mammalian target of rapamycin (mTOR) inhibitor, everolimus with endocrine therapy have resulted in a redefinition of the clinical treatment pathway in the metastatic setting. This review details the current endocrine therapy utilized in both early and advanced disease, as well as exploring potential new targets which modulate pathways of resistance, as well as agents which aim to modulate adrenal derived steroidogenic hormones.
CitationBreast cancer: current and future endocrine therapies. 2014, 382 (1):695-723 Mol Cell Endocrinol
JournalMolecular and Cellular Endocrinology
- Endocrine therapy and other targeted therapies for metastatic breast cancer.
- Authors: Hussain SA, Palmer DH, Moon S, Rea DW
- Issue date: 2004 Dec
- Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
- Authors: Brufsky AM
- Issue date: 2014 Jul-Aug
- A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
- Authors: Jerusalem G, Bachelot T, Barrios C, Neven P, Di Leo A, Janni W, de Boer R
- Issue date: 2015 Feb
- Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
- Authors: Jordan VC, Brodie AM
- Issue date: 2007 Jan
- The curability of breast cancer and the treatment of advanced disease.
- Authors: Guarneri V, Conte PF
- Issue date: 2004 Jun